Short answer
IDEAYA Biosciences, Inc. (IDYA) filed an 8-K current report with the SEC on June 1, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Investor presentation tied to the 2026 ASCO Annual Meeting.
IDEAYA Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Investor presentation tied to the 2026 ASCO Annual Meeting
- Clinical-development updates may influence investor views on IDEAYA’s oncology pipeline
- Presentation furnished as Exhibit 99.1 for detailed study and program information
Item 8.01 · Other Events
- Phase 2/3 OptimUM-02 met its primary endpoint, with median PFS 6.9 months versus 3.1 months for investigator-choice therapy
- Darovasertib combination reduced progression risk 58% by BICR and 64% by investigator assessment
- ORR reached 37.1% versus 5.8% by BICR, supporting substantial efficacy differentiation in first-line HLA*A2:01-negative mUM
- Grade 3/4 treatment-related adverse events were 40.6% versus 37.0%, while serious events were lower at 9.2% versus 25.0%
- NDA filing expected in second half of 2026 after FDA Real-Time Oncology Review presubmission in May
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other IDEAYA Biosciences, Inc. 8-K filings
Get the next IDYA 8-K as it lands
Follow IDYA for push alerts, or ask the research agent what this filing means.